Australia markets closed

TEVA Mar 2025 17.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
2.6700+0.4000 (+17.62%)
At close: 03:14PM EDT
Full screen
Previous close2.2700
Open2.6700
Bid2.4800
Ask2.9000
Strike17.00
Expiry date2025-03-21
Day's range2.6700 - 2.6800
Contract rangeN/A
Volume10
Open interest209
  • Reuters

    Teva sues Corcept over mifepristone 'monopoly' for rare disorder

    Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome. The lawsuit said Corcept and specialty pharmacy Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn.” Teva accused Corcept of "paying bribes and kickbacks" to physicians to keep them prescribing brand Korlym.

  • Business Wire

    Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

    TEL AVIV, Israel, June 04, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time.

  • Zacks

    TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

    TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.